Sernova Biotherapeutics (SEOVF) Stock Price, News & Analysis

Company Overview

Sernova Biotherapeutics is a clinical‐stage biotechnology company focused on developing and commercializing cell‐based therapeutic technologies for patients with chronic and life‐threatening diseases. Headquartered in London, Ontario, Canada, the firm is advancing an implantable device platform designed to support the long-term survival and function of therapeutic cells. The company’s lead product candidate, known as the Cell Pouch System, is engineered to create a vascularized environment in which transplanted cells can thrive, with an initial emphasis on treating patients with type 1 diabetes.

In its core program, Sernova has initiated a Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch System in individuals with type 1 diabetes who require islet cell transplantation. Beyond diabetes, the company is exploring broader applications of its delivery platform, including therapies for hemophilia and other endocrine and metabolic disorders. Preclinical studies have demonstrated the ability of the Cell Pouch to promote cell engraftment and function, positioning Sernova’s technology as a potential alternative to conventional chronic drug administration.

Founded in 2008 and formerly known as Sernova Corp, the company rebranded as Sernova Biotherapeutics in late 2023 to better reflect its evolving pipeline. Sernova conducts its clinical activities across North America and Europe, collaborating with academic and clinical research centers to advance its trials. Leading the organization is Dr. Philip A. Toleikis, Sernova’s founder, president and chief executive officer, who brings more than two decades of experience in regenerative medicine and cell‐based therapy development.

Key Stats

• Today's Range: $0.13 to $0.13
• 50-Day Range: $0.11 to $0.16
• 52-Week Range: $0.10 to $0.21
• Volume: 1,034 shs
• Average Volume: 21,565 shs
• Market Capitalization: $41.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SEOVF Stock Analysis - Frequently Asked Questions

How have SEOVF shares performed this year?

Sernova Biotherapeutics' stock was trading at $0.15 at the beginning of 2025. Since then, SEOVF stock has decreased by 14.9% and is now trading at $0.1276.

How were Sernova Biotherapeutics' earnings last quarter?

Sernova Biotherapeutics Inc. (OTCMKTS:SEOVF) released its quarterly earnings data on Monday, September, 15th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.00.

How do I buy shares of Sernova Biotherapeutics?

Shares of SEOVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 9/15/2025
• Today: 9/21/2025
• Fiscal Year End: 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SEOVF
• CIK: 1491434
• Web: www.sernova.com
• Phone: (519) 858-5184
• Fax: 519-858-5184
• Employees: N/A
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -378.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.12
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -4.25

Miscellaneous

• Outstanding Shares: 328,480,000
• Free Float: N/A
• Market Cap: $41.91 million
• Optionable: Not Optionable
• Beta: 1.07